Michael M. Kellen

Chairman & Co-Chief Executive Officer at Bleichroeder LP

Michael M. Kellen

Michael M. Kellen

Chairman & Co-Chief Executive Officer at Bleichroeder LP

Overview
Career Highlights

Bleichroeder LP
First Eagle Holdings, Inc.

RelSci Relationships

994

Primary Location

Manhattan, New York

Number of Boards

8

Relationships
RelSci Relationships are individuals Michael M. Kellen likely has professional access to. A relationship does not necessarily indicate a personal connection.

President, Co-Chief Executive Officer & Chief Compliance Officer at Bleichroeder LP

Relationship likelihood: Strong

President, Chief Executive Officer & Director at First Eagle Holdings, Inc.

Relationship likelihood: Strong

Principal & Founder at BAM Consulting LLC

Relationship likelihood: Strong

Fund Advisor at First Eagle Investment Management LLC

Relationship likelihood: Strong

Senior Managing Director, Private Equity Group at The Blackstone Group, Inc.

Relationship likelihood: Strong

Member, Board of Directors at Melanoma Research Alliance

Relationship likelihood: Strong

Senior Fellow & Executive Director Emeritus at American Academy in Berlin GmbH

Relationship likelihood: Strong

Professional at Consultants International Group, Inc.

Relationship likelihood: Strong

Member, Board of Trustees at Hospital for Special Surgery

Relationship likelihood: Strong

Former Partner at The Goldman Sachs Group, Inc.

Relationship likelihood: Strong

Paths to Michael M. Kellen
Potential Connections via
Relationship Science
You
Michael M. Kellen
Chairman & Co-Chief Executive Officer at Bleichroeder LP
Family Members
Spouse
Member, Board of Directors at Melanoma Research Alliance

The Melanoma Research Alliance (MRA) is the largest non-profit funder of melanoma research. Since its founding in 2007, MRA has committed $100 million in funding to advance our understanding of this disease. MRA funds projects in the areas of prevention, diagnosis, and treatment, with the majority of funding allocated for melanoma treatment.

Education
BA
Class of 1966

The oldest corporation in the Western Hemisphere is the Harvard Corporation, known formally as the President and Fellows of Harvard College. It is the smaller of Harvard’s two governing boards; the other is the Board of Overseers. Following are the members of the Harvard Corporation.

Career History
Chairman & Co-Chief Executive Officer
2019 - Current

Bleichroeder seeks to achieve capital appreciation by investing client assets in a portfolio of stocks, bonds, notes, options and other securities and derivatives, commodities and currencies. Their investment strategy is to purchase securities of companies that firm believes are attractive investment opportunities, at advantageous prices when the market presents the opportunity. Bleichroeder will generally sell investments if it believes that the price of the investments adequately reflects potential future events. Their investment philosophy contemplates bottom-up, research-oriented value investing. The firm utilizes a global investment approach and may invest in US and non-US investments.

Portfolio Manager
Current

FEIM is a global, value-oriented investment manager that seeks to produce consistent absolute returns over the long-term without regard for industry benchmarks. They construct well-diversified portfolios through cautious security selection with an emphasis on risk aversion. FEIM focuses on investments with a substantial margin of safety, healthy balance sheets and clear business models. They employ bottom-up security analysis that is independent of broad market conditions or industry trends and focuses on downside protection. FEIM currently manages the following primary investment strategies: Global Value and International Value, High Yield, Gold, US Value, and Global Income Builder.

Fund Advisor
? - 1991

Iridian Asset Management is an independently owned, value-oriented investment management firm focused on active equity investment strategies for institutional investors, including foundations and endowments, corporate and public pension funds, sub-advised and Taft Hartley funds. As of September 30, 2012, assets under management totalled $7.7 billion in U.S. mid-cap, large-cap and small-cap equity strategies. Iridian was founded in 1996 by David Cohen and Harold Levy, two seasoned investment professionals who have worked side-by-side in the investment industry for over 20 years. Our unique "private business value" approach to investing, which drives our mid-cap and large-cap strategies, has its roots in their early investment careers, which encompassed direct experience in private equity, venture capital, distressed debt and bankruptcy takeovers. In analyzing investment opportunities, our founders learned the importance of focusing on cash-related metrics and in-depth, critical assessment of a company's management — two key factors that have been fundamental in shaping a shared and distinctive investment philosophy. In December 2009, the co-portfolio management team of Jordan D. Alexander and Stephen A. Friscia, Jr. joined Iridian to manage a Small-Cap Value strategy. Jordan and Stephen have worked together since 1998 and have co-managed small cap value strategies as a team since 2000. Today, Iridian is built around a collaborative team of experienced investment professionals managing a range of traditional investment strategies for institutional investors.

Non-Profit Donations & Grants

Learn how non-profit organizations benefit from RelSci
$100K - $250K
2015

The Melanoma Research Alliance (MRA) is the largest non-profit funder of melanoma research. Since its founding in 2007, MRA has committed $100 million in funding to advance our understanding of this disease. MRA funds projects in the areas of prevention, diagnosis, and treatment, with the majority of funding allocated for melanoma treatment.

$250K - $500K
2014

The Melanoma Research Alliance (MRA) is the largest non-profit funder of melanoma research. Since its founding in 2007, MRA has committed $100 million in funding to advance our understanding of this disease. MRA funds projects in the areas of prevention, diagnosis, and treatment, with the majority of funding allocated for melanoma treatment.

$50K - $100K
2013

The Melanoma Research Alliance (MRA) is the largest non-profit funder of melanoma research. Since its founding in 2007, MRA has committed $100 million in funding to advance our understanding of this disease. MRA funds projects in the areas of prevention, diagnosis, and treatment, with the majority of funding allocated for melanoma treatment.

Political Donations
$2,300
2008

Former Senator from New York

$5,000
2004

Former Senator from Massachusetts

$1,000
1992

Former Faculty Member at Harvard University - Harvard Medical School

Transactions
Details Hidden

New Eagle Holdings LLC raised money in a private placement transaction

Details Hidden

21 APRIL FUND, L.P. raised money in a private placement transaction

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Michael M. Kellen. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Michael M. Kellen's profile does not indicate a business or promotional relationship of any kind between RelSci and Michael M. Kellen.